Aspirin failure in patients presenting with acute cerebrovascular ischaemia

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 240-247

  Halawani, Saeed H M ^a   Williams, David J P ^a   Webster, John ^a   Greaves, Michael ^a   Ford, Isobel ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antiplatelet agents; Aspirin resistance; Platelet pharmacology; Stroke prevention

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; COLLAGEN; CREATININE; D DIMER; FIBRINOGEN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BLOOD ANALYSIS; BRAIN ISCHEMIA; COLLAGEN METABOLISM; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL CARE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; URINALYSIS; URINE LEVEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ARACHIDONIC ACID; ASPIRIN; BRAIN ISCHEMIA; DRUG RESISTANCE; FEMALE; HUMANS; MALE; P-SELECTIN; PATIENT COMPLIANCE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THROMBOXANE B2;

EID: 79961046006     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-01-0045     Document Type: Article

References (35)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, strokes in high-risk patients. Br Med J 2002; 324: 71-86.
2. Hankey GJ, Eikelboom JW. Aspirin Resistance may be a cause of recurrent vascular events in patients taking aspirin. Br Med J 2004; 328: 477-479.
3. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5: 230-237.
4. Grove EL, Hvas A-M, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
5. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
6. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-1311.
7. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
8. Gum P, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
9. Gengo FM, Rainka M, Robson M, et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol 2008; 48: 335-343.
10. O'Connor PJ. Improving medication adherence. Arch Intern Med 2006; 166: 1802-1804.
11. Rajagopalan S, Ford I, Bachoo P, et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost 2007; 5: 2028-2035.
12. Webster SE, Payne DA, Jones CI, et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 2004; 40: 463-468.
13. Alberts M, Bergman D, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004; 35: 175-178.
14. Berrouschot J, Schwetlick B, von Twickel G, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113: 31-35.
15. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336.
16. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-1005.
17. Komiya T, Kudo M, Urabe T, et al. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke 1994; 25: 2337-2342.
18. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
19. Frelinger AL, Furman M, Linden M, et al. Residual arachidonic-acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway. Circulation 2006; 113: 2888-2896.
20. Frelinger AL, Li Y, Linden M, et al. Aspirin "resistance": Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-2044.
21. Maree A, Fitzgerald D. Variable platelet response to aspirin and clopidogrel. Circulation 2007; 115: 2196-2207.
22. Gum P, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
23. Harrison P, Segal H, Silver L, et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119-124.
24. Meiklejohn DJ, Vickers MA, Morrison ER, et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001; 112: 621-631.
25. Perneby C, Wallen HN, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
26. McCabe DJ, Harrison P, Sidhu PS, et al. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004; 126: 861-869.
27. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-191.
28. Lordkipanidzé M. Why an aspirin a day no longer keeps the doctor away Thromb Haemost 2011; 105: 209-210.
29. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
30. Snoep JD, Hovens M, Eikenboom J, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007; 167: 1593-1599.
31. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
32. Eikelboom JW, Hankey GJ, Thom J, et al. on behalf of the CHARISMA Investigators. Incomplete inhibition of thromboxane biosynthesis by acetyl salicylic acid: Determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
33. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688.
34. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J ThrombHaemost 2006; 4: 1271-1278.
35. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007; 28: 1673-1675.